About: Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production
Creator	Jordan, Ingo Genzel, Yvonne Reichl, Udo Tapia, Felipe Engineering, Bioprocess Behrendt, Ilona Gränicher, Gwendal
Source	Medline; PMC
abstract	Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination against various challenging pathogens or the treatment of some types of cancers. Because this vector is unable to replicate in human recipients, a high amount of virions per dose is required for vaccination and gene therapy. Upstream process intensification combining perfusion technologies, the avian suspension cell line AGE1.CR.pIX and the virus strain MVA‐CR19 is an option to obtain very high MVA yields. Here we compared different options for cell retention in perfusion mode using conventional stirred‐tank bioreactors including an alternating tangential flow filtration system, an acoustic settler and an inclined settler. The last two options allowed continuous MVA virus harvesting. Furthermore, we studied hollow‐fiber based bioreactors and an orbital‐shaken bioreactor in perfusion mode, both available for single‐use. Productivity for the virus strain MVA‐CR19 was compared to results from batch and continuous production reported in literature. Our results demonstrate that MVA virus is highly stable at 37°C in cell culture so that cell retention devices are only required to maximize cell concentration but not for continuous harvesting. Using a stirred‐tank bioreactor, a perfusion strategy during the whole run with working volume expansion after virus infection resulted in the highest yields. Overall, infectious MVA virus titers of 2.1–16.5 × 10(9) virions/mL were achieved in these intensified processes. Taken together, the study shows a novel perspective on high‐yield MVA virus production in conventional bioreactor systems linked to various cell retention devices and addresses options for process intensification including fully single‐use perfusion platforms. This article is protected by copyright. All rights reserved
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1002/biot.202000024
bibo:pmid	32762152
has license	no-cc
sha1sum (hex)	7c9c66539b884562d4b7231bdc12993990bba61a
schema:url	https://doi.org/10.1002/biot.202000024
resource representing a document's title	Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production
has PubMed Central identifier	PMC7435511
has PubMed identifier	32762152
schema:publication	Biotechnol J
resource representing a document's body	covid:7c9c66539b884562d4b7231bdc12993990bba61a#body_text
is schema:about of	named entity 'continuous production' named entity 'human' named entity 'settler' named entity 'harvesting' named entity 'Productivity' named entity 'retention' named entity 'virus' named entity 'volume' named entity 'concentration' named entity 'demonstrate' named entity 'options' named entity 'Because' named entity 'cell' named entity 'MVA' named entity 'studied' named entity 'acoustic' named entity 'cancers' named entity 'inclined' named entity 'literature' named entity 'single-use' named entity 'cell' named entity 'options' named entity 'replicate' named entity 'MVA' named entity 'gene therapy' named entity 'MVA' named entity 'cell culture' named entity 'virus infection' named entity 'bioreactor' named entity 'pathogens' named entity 'bioreactor' named entity 'virus' named entity 'virus' named entity 'bioreactor' named entity 'perfusion' named entity 'vector' named entity 'ATF' named entity 'perfusion' named entity 'ammonium' named entity 'perfusion' named entity 'insulin-like growth factor' named entity 'supernatant' named entity 'perfusion' named entity 'MVA' named entity 'infection' named entity 'supernatant' named entity 'infection' named entity 'MVA' named entity 'MVA' named entity '37°C' named entity 'perfusion' named entity 'gene therapy' named entity 'seed' named entity 'MVA' named entity 'STRs' named entity 'process intensification' named entity 'ATF' named entity 'supernatant' named entity 'perfusion' named entity '21 days' named entity 'MVA' named entity 'ATF' named entity 'STR' named entity 'virions' named entity '0.01' named entity 'Germany' named entity 'ATF' named entity 'perfusion' named entity 'SFs' named entity 'recombinant protein' named entity 'bioreactors' named entity 'perfusion' named entity 'OSB' named entity 'genomic information' named entity 'perfusion'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software